Mortality Among Injecting Drugs Users - A Follow-up Study Of Injecting Drug User Cohorts.
Funder
National Health and Medical Research Council
Funding Amount
$47,500.00
Summary
This study will follow-up injecting drug users that participated in research in the 1990s and 2000s to examine mortality rates in these groups over time. Identifying information from these studies will be cross-referenced with National Death Index data to determine participants that died and the dates of their death. This study will be the first in Australia to determine mortality rates over time in a defined cohort of injecting drug users outside drug treatment settings. Studying a defined grou ....This study will follow-up injecting drug users that participated in research in the 1990s and 2000s to examine mortality rates in these groups over time. Identifying information from these studies will be cross-referenced with National Death Index data to determine participants that died and the dates of their death. This study will be the first in Australia to determine mortality rates over time in a defined cohort of injecting drug users outside drug treatment settings. Studying a defined group overcomes some of the problems associated with mortality rate estimates based simply on the number of injecting drug-related deaths. Although the number of deaths can be found, the number of people at risk of injecting drug-related death is unclear because of the hidden nature of drug use and the dynamic characteristics of drug use and drug markets. The examination of mortality trends among injecting drug users over time can provide insights regarding changes in drug use patterns and markets. For example, this study will examine changes in injecting drug use mortality across periods of high heroin availability in the late '90s and periods of interrupted heroin supply - the heroin 'drought' - from 2000 onwards. In addition, factors related to injecting drug-related mortality can be explored by comparing the characteristics of injecting drug users that died and those that survived, such as drug use and drug treatment histories, co-morbidities such as mental illness and socio-demographic backgrounds. This information can inform overdose prevention and harm reduction strategies by identifying individuals most at risk of injecting drug-related mortality. This study will also draw attention to the significant public health burden of injecting drug use. In addition, by comparing the results from this study with other similar studies from overseas, we can more reliably compare mortality among groups of Australian injecting drug users with their peers in other countries.Read moreRead less
Is The Incidence Of Heart Attack Still Decreasing In Australia? Developing More Reliable Methods For Monitoring Trends In Myocardial Infarction And Coronary Heart Disease
Funder
National Health and Medical Research Council
Funding Amount
$762,021.00
Summary
Our study is a collaboration between the University of WA and the Australian Institute of Health and Welfare to investigate population trends in incidence and outcomes of heart disease and its major sub-groups including heart attack, angina and chest pain. Using linked data from WA, we will identify the sub-groups for which trends over time are a realistic estimate of the true population trends. These will be applied to national data to monitor heart disease more accurately in Australia.
Investigating The Relationships Between Cannabis And Other Drug Use, Mental Health, Early-life Factors And Life-course Outcomes: Integrative Analyses Of Data From Four Australasian Cohort Studies
Funder
National Health and Medical Research Council
Funding Amount
$292,097.00
Summary
The current study will be the first of its kind to use integrative data analyses _ a highly innovative approach _ to pool data from four large and long-running Australasian cohort studies to better understand the link between cannabis use and later-life outcomes. Dramatically improved knowledge of these relationships will create a clearer picture of the interventions required to reduce the harms associated with cannabis use.
Advancing The Epidemiology Of Coronary Heart Disease: Reliable Monitoring, Secondary Prevention And Future Projections
Funder
National Health and Medical Research Council
Funding Amount
$314,644.00
Summary
Coronary heart disease imposes a significant health care burden in Australia, and there have been major changes to the way in which this disease is diagnosed and treated. This project will develop a new method for accurate monitoring of the burden of coronary heart disease nationally, will assess the effectiveness of current drug treatments for people with coronary heart disease and estimate future rates of coronary heart disease in the whole population.
Injecting Drug Use, Incarceration, Infection: Investigating Opportunities For Public Health Interventions In Disadvantaged Populations
Funder
National Health and Medical Research Council
Funding Amount
$329,564.00
Summary
New knowledge required to address infectious diseases and mental illness among two disadvantaged and overlapping groups -people who inject drugs (PWID) and prisoners – will be produced: Cross sectional and longitudinal studies will examine HIV risk in specific populations; A system to track the emergence of injecting will be developed; The global scale of mental illness and TB among PWID will be determined; and how to improve coverage and delivery of TB prevention and treatment will be explored.
Prevention Of Multi-drug Resistant Tuberculosis In A High Prevalence Setting: ‘Connecting The DOTS’ In Vietnam
Funder
National Health and Medical Research Council
Funding Amount
$3,382,020.00
Summary
The close contacts of people with multi-drug resistant tuberculosis (MDR-TB) have a high risk of developing the disease. The V-QUIN MDR-TB Trial will evaluate the effectiveness of an oral antibiotic (levofloxacin) in preventing drug resistant TB among infected household contacts of TB patients. Household contacts from 10 Provinces in Vietnam will be randomly allocated to receive six-months of either levofloxacin or a placebo, and then followed for two years to see if they develop tuberculosis.